Meeting
2016 Genitourinary Cancers Symposium
Imaging response during therapy (tx) with radium-223 (Ra-223) for castrate resistant prostate cancer (CRPC) with bone metastases (BM).
Authors
Daniel Keizman
Genitourinary Oncology Service, Division of Oncology, Meir Medical Center, Sackler School of Medicine, Tel Aviv University, Kfar-Saba, Israel
Daniel Keizman , Avivit Peer , Avivit Neumann , Eli Rosenbaum , Victoria Neiman , Maya Gottfried , Iryna Kuchuk , David Sarid , Eliahu Gez , Wilmosh Mermershtain , Keren Rouvinov
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 34, 2016 (suppl 2S; abstr 282)
DOI
10.1200/jco.2016.34.2_suppl.282
Abstract #
282
Poster Bd #
M9
Abstract Disclosures
Similar Posters
Poster
2019 Genitourinary Cancers Symposium
Radium 223 treatment in metastatic castrate-resistant prostate cancer: Impact of sequencing on survival—Real-world outcomes from a single UK centre.
First Author: Xue Yan Jiang
Poster
2018 Genitourinary Cancers Symposium
Patterns of progression in bone and soft tissue following treatment with Ra-223 in metastatic castrate resistant prostate cancer (mCRPC).
First Author: Megan Ann McNamara
Poster
2020 Genitourinary Cancers Symposium
The effect of docetaxel, enzalutamide, abiraterone, and radium-223 on cognitive function in older men with metastatic castrate-resistant prostate cancer (mCRPC).
First Author: Shabbir M.H. Alibhai
Poster
2020 Genitourinary Cancers Symposium
New patient-derived models of castrate-sensitive and castrate-resistant prostate cancer.
First Author: Mitchell Lawrence